Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Rick Brown, vice president of Immunology and Infectious Diseases at Genentech, discusses how the company is tackling the challenges of discovering novel antibiotics.
Martin VanTrieste, CEO of Civica Rx and former chief quality officer for Amgen, discusses how his hospital-backed non-profit generic drug company plans to bring stability to the generic drug market.
Ida Sim, Vivli co-founder and UCSF informatician, discusses the need for a neutral broker platform that can facilitate access to and analysis of industry and academic patient-level clinical trial data.
Penny Heaton, CEO of the Bill and Melinda Gates Medical Research Institute, discusses how the recently launched non-profit biotech will tackle the translational science of TB, malaria and diarrhoeal diseases.
Saurabh Saha, head of Translational Medicine at Bristol-Myers Squibb, discusses how new tools are opening up translational opportunities in immuno-oncology
Amy Abernethy, CSO at Flatiron Health, talks about how cleaned up and curated real-world data stands to transform clinical trials, drug regulation, competition in the health-care market and drug prices.
Norbert Bischofberger, former CSO of Gilead, discusses antiviral opportunities, Gilead's pivot to oncology and the need for a societal discussion of drug costs.
George Yancopoulos, CSO of Regeneron, discusses his 30 years at Regeneron, the company's evolving growth plans and the recent launch of a precompetitive collaboration to sequence 500,000 UK Biobank exomes.
Fiona Marshall — co-founder of Heptares, former chief scientific officer of Sosei and soon to be lead of Merck & Co.'s new research facility in London — looks back on 30 years of GPCRs, and looks forward to the emerging therapeutic opportunities these targets still offer.
Morgan Sheng, Vice President of Neuroscience at Genentech, discusses his continued faith in the amyloid hypothesis, the promise of the genetics of neurodegenerative disorders and the overlap between psychiatric disease and neurodegeneration.
